NAFDAC Issues Notice of Fake Augmentin in Nigeria

0

CEM REPORT, HEALTH | The National Agency for Food and Drug Administration and Control (NAFDAC) has warned the general public against a suspected fake Augmentin 625mg tablets in circulation within the country.

The agency notes that the particular fake Augmentin drug bears an inscription written on the label.

“The product failed short of the labelling requirements. No inscription “manufactured by” is written on the label -only the address,” NAFDAC said in a statement.

“Manufacturing and expiry dates do not meet the acceptable format. No MAS scratch number for verification. The logo “gsk” is not properly positioned as on the original. The listed information indicates the product is falsified and counterfeited.”

The agency said it has notified all its formations in the 36 states in the country to carry out surveillance and take the fake drug from circulation within the country.

NAFDAC noted that the genuine Augmentin 625mg has legible product labelling information which includes expiry and manufacturing dates, batch number, and a NAFDAC registration number.

The agency also urged all wholesalers, distributors, and pharmacies to be vigilant and avoid infiltration of the falsified product, adding that medicines should be obtained from authorized and licensed suppliers.

“The products’ authenticity, physical condition, and labels should be carefully checked.”

NAFDAC implores all healthcare providers to ensure vigilance to prevent the administration of falsified products to unsuspecting patients.

NAFDAC also urged the general public in possession of the suspected counterfeit product to discontinue sale or use and submit the stock to its nearest office.

“Healthcare providers and the public should notify the nearest NAFDAC office of any information concerning the distribution, sale, and use of the falsified version of the Augmentin product. Report any suspicion of adverse drug reaction and substandard and falsified medicines to NAFDAC.”

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments